精准与转化医学

小鼠心肌层注射方法的改进

展开
  • 苏州大学附属第三医院, 心血管内科, 江苏 常州 213003
周学中(1974—), 男, 副主任医师, 研究方向为冠心病介入治疗. E-mail: zxzjszj@126.com

收稿日期: 2017-10-30

  网络出版日期: 2017-12-30

基金资助

国家自然科学基金青年基金资助项目(81700351); 常州市卫生计生委青年人才科技资助项目(QN201707)

Improvement of myocardial layer injection in mice

Expand
  • Cardiovascular Department, Third Affiliated Hospital of Soochou University, Changzhou 213003, Jiangsu, China

Received date: 2017-10-30

  Online published: 2017-12-30

摘要

探索心肌有效稳定的给药方式, 达到优化手术的均一性和可重复性. 采用改良后的注射针头, 分别向小鼠心肌层注射伊文思蓝(Evans Blue)和带绿色荧光蛋白的慢病毒, 结果发现伊文思蓝和慢病毒能够全部存留在心肌中, 而且慢病毒能够在整个心脏中稳定长期地表达绿色荧光蛋白. 研究表明, 改良的心肌层注射方式均一性好, 手术成功率高, 可用于心血管研究和基因治疗.

本文引用格式

王惠, 赵蓉, 周学中 . 小鼠心肌层注射方法的改进[J]. 上海大学学报(自然科学版), 2017 , 23(6) : 835 . DOI: 10.12066/j.issn.1007-2861.1969

Abstract

An improved myocardial layer injection acts as an effectual mode of administration was established. Used improved syringe, Evans Blue and green fluorescent protein(GFP) labeled lentivirus were injected in to mouse myocardial layer. Evans Blue and lentivirus were found to be stored in mouse myocardial layer, and GFP could stably express in the whole heart for a long time. In conclusion, an improved myocardial layer injection may be used to cardiovascular disease (CVD) research and gene therapy research because of the good uniformity and high success rate.

参考文献

[1] Benjamin E J, Blaha M J, Chiuve S E, et al. Heart disease and stroke statistics-2017 update: a report from the american heart association [J]. Circulation, 2017, 135(10): e634-e1003.

[2] Catucci M, Prete F, Bosticardo M, et al. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome [J]. Gene Therapy, 2012, 19(12): 1150-1158.

[3] Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure [J]. Circulation Research, 2012, 110(5): 777-793.

[4] Su C H, Wu Y J, Wang H H, et al. Nonviral gene therapy targeting cardiovascular system[J]. American Journal of Physiology Heart & Circulatory Physiology, 2012, 303(6): 629-638.

[5] Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery [J]. Annual Review of Biomedical Engineering, 2007, 9: 415-447.

[6] Bei Y, Xu T, L¨U D, et al. Exercise-induced circulating extracellular vesicles protect against cardiac ischemia-reperfusion injury [J]. Basic Research in Cardiology, 2017, 112(4): 38.

[7] Eulalio A, Mano M, dal Ferro M, et al. Functional screening identifies miRNAs inducing cardiac regeneration [J]. Nature, 2012, 492(7429): 376-381.

[8] Santiagortiz J L, Schaffer D V. Adeno-associated virus (AAV) vectors in cancer gene therapy [J]. Journal of Controlled Release, 2016, 240: 287-301.

[9] Prasad K M, Xu Y, Yang Z, et al. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution [J]. Gene Therapy,

2011, 18(1): 43-52.

[10] Pleger S T, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues postischemic heart failure in a preclinical large animal model [J]. Science Translational Medicine, 2011, 3(92): 92ra64.

[11] Bey K, Ciron C, Dubreil L, et al. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders [J]. Gene Therapy, 2017,

24(5): 325-332.

[12] Martini S V, Silva A L, Ferreira D, et al. Tyrosine mutation in AAV9 capsid improves gene transfer to the mouse Lung [J]. Cellular Physiology and Biochemistry, 2016, 39(2): 544-553.

[13] Chen B D, He C H, Chen X C, et al. Targeting transgene to the heart and liver with AAV9 by different promoters [J]. Clininal and Experimental Pharmacology and Physiology, 2015, 42(10): 1108-1117.

文章导航

/